Trial Profile
A phase 1/2 study that combines stereotactic ablative radiation to prostate cancer metastases, followed by treatment with ADXS-PSA
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2023
Price :
$35
*
At a glance
- Drugs ADXS 31142 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
- 01 Dec 2015 According to the Advaxis Inc. media release, FDA has placed ADXS- PSA trials on clinical hold.
- 01 Dec 2015 Status changed from planning to suspended, according to the Advaxis Inc. media release.